A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. (15th April 2016)
- Record Type:
- Journal Article
- Title:
- A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. (15th April 2016)
- Main Title:
- A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film
- Authors:
- Bunge, Katherine E.
Dezzutti, Charlene S.
Rohan, Lisa C.
Hendrix, Craig W.
Marzinke, Mark A.
Richardson-Harman, Nicola
Moncla, Bernard J.
Devlin, Brid
Meyn, Leslie A.
Spiegel, Hans M.L.
Hillier, Sharon L. - Abstract:
- Abstract : Background: Films may deliver antiretroviral drugs efficiently to mucosal tissues. In this first in-human trial of a vaginal film for delivering the nonnucleoside reverse transcriptase inhibitor dapivirine, safety, pharmacokinetics, and pharmacodynamics of film and gel formulations were compared with placebo. Methods: Sixty-one healthy HIV-negative women were randomized to daily dapivirine (0.05%) or placebo gel, or dapivirine (1.25 mg) or placebo film for seven days. The proportion of participants experiencing grade 2 and higher adverse events related to study product were compared. Plasma dapivirine concentrations were quantified. Paired cervical and vaginal tissue biopsies obtained ∼2 hours after the last dose were measured for tissue drug concentration and exposed to HIV in an ex vivo challenge assay. Results: Two grade 2 related adverse events occurred in the placebo film group. Women randomized to gel and film products had 4 log10 higher of dapivirine in cervical and vaginal tissues than plasma. Although gel and film users had comparable plasma dapivirine concentrations, tissue concentrations of dapivirine were 3–5 times higher in the gel users when compared with film users. HIV replication in the ex vivo challenge assay was significantly reduced in vaginal tissues from women randomized to dapivirine film or gel; furthermore, tissue drug concentrations were highly correlated with HIV protection. Women rated the film more comfortable with less leakage butAbstract : Background: Films may deliver antiretroviral drugs efficiently to mucosal tissues. In this first in-human trial of a vaginal film for delivering the nonnucleoside reverse transcriptase inhibitor dapivirine, safety, pharmacokinetics, and pharmacodynamics of film and gel formulations were compared with placebo. Methods: Sixty-one healthy HIV-negative women were randomized to daily dapivirine (0.05%) or placebo gel, or dapivirine (1.25 mg) or placebo film for seven days. The proportion of participants experiencing grade 2 and higher adverse events related to study product were compared. Plasma dapivirine concentrations were quantified. Paired cervical and vaginal tissue biopsies obtained ∼2 hours after the last dose were measured for tissue drug concentration and exposed to HIV in an ex vivo challenge assay. Results: Two grade 2 related adverse events occurred in the placebo film group. Women randomized to gel and film products had 4 log10 higher of dapivirine in cervical and vaginal tissues than plasma. Although gel and film users had comparable plasma dapivirine concentrations, tissue concentrations of dapivirine were 3–5 times higher in the gel users when compared with film users. HIV replication in the ex vivo challenge assay was significantly reduced in vaginal tissues from women randomized to dapivirine film or gel; furthermore, tissue drug concentrations were highly correlated with HIV protection. Women rated the film more comfortable with less leakage but found it more difficult to insert than gel. Discussion: Both film and gel delivered dapivirine at concentrations sufficient to block HIV ex vivo. This proof-of-concept study suggests film formulations for microbicides merit further investigation. Abstract : Supplemental Digital Content is Available in the Text. … (more)
- Is Part Of:
- Journal of acquired immune deficiency syndromes. Volume 71:Number 5(2016)
- Journal:
- Journal of acquired immune deficiency syndromes
- Issue:
- Volume 71:Number 5(2016)
- Issue Display:
- Volume 71, Issue 5 (2016)
- Year:
- 2016
- Volume:
- 71
- Issue:
- 5
- Issue Sort Value:
- 2016-0071-0005-0000
- Page Start:
- Page End:
- Publication Date:
- 2016-04-15
- Subjects:
- microbicide -- vaginal film -- dapivirine -- HIV prevention
AIDS (Disease) -- Periodicals
Acquired Immunodeficiency Syndrome -- Periodicals
AIDS (Disease)
Periodicals
616.9792005 - Journal URLs:
- http://journals.lww.com/jaids/pages/default.aspx ↗
http://www.jaids.com ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/QAI.0000000000000897 ↗
- Languages:
- English
- ISSNs:
- 1525-4135
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4644.422000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4959.xml